Follicular Lymphoma Market

The ‘Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030′ report from DelveInsight provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as market trends in the US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Some of the Key Highlights from the Follicular Lymphoma Market Report

• According to Mozas et al (2020) study, “Patterns of change in treatment, responsiveness, and prognosis in patients with Follicular Lymphoma throughout the previous four decades: a single-center experience,” 54 percent of Follicular Lymphoma patients were refractory or had relapse/progression during follow-up.

• The incidence of Follicular Lymphoma in Japan was 2.80 per 100,000 people, according to a study by Fujishima et al. (2018) titled “Incidence Rate, Subtype Frequency, and Occurrence Site of Malignant Lymphoma in the Gastrointestinal Tract: Population-Based Analysis in Miyagi, Japan.”

• Pipeline therapies in the Follicular Lymphoma market include Tazverik(Tazemetostat) (Epizyme), Abexinostat (Xynomic Pharmaceuticals), ME-401 (MEI Pharma), Tisagenlecleucel (Novartis Pharmaceuticals), Parsaclisib (IBI376) (Innovent Biologics) and others.

• Major companies involved in the Follicular Lymphoma market include Epizyme, Xynomic Pharmaceuticals, MEI Pharma, Novartis Pharmaceuticals, Innovent Biologics, among others.

Learn more by requesting sample @ Follicular Lymphoma Market

The Follicular Lymphoma market report also examines existing Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs in order to gather the best of the prospects and assess the market’s underlying potential.

Follicular Lymphoma: Disease Overview

Follicular Lymphoma (FL) is a cancer that affects lymphocytes, which are white blood cells. The cancer is caused by the unregulated division of centrocytes and centroblasts, two types of B-cells. These cells generally reside in the germinal centres of lymphoid tissues such as lymph nodes, where they form follicles (nodular swirls of several types of lymphocytes). FL malignant cells penetrate tissues and create follicular or follicle-like formations. These structures are frequently the cancer’s most prominent histological feature.

Follicular Lymphoma Epidemiology Segmentation

• Follicular Lymphoma Total Incident Cases

• Follicular Lymphoma Risk-Specific Incident Cases

• Follicular Lymphoma Stage-Specific Incident Cases

• Follicular Lymphoma Mutation-Specific Incident Cases

• Follicular Lymphoma Refractory/Relapsed Incident Cases

• Follicular Lymphoma Treatable Cases

Follicular Lymphoma Treatment Landscape

Depending on the severity of the associated symptoms and the rate of cancer growth, there are a variety of treatment options for Follicular Lymphoma. Chemotherapy, radiation therapy, immunotherapy, and stem cell transplant are among the therapies used to treat Follicular Lymphoma. Patients with early-stage Follicular Lymphoma (Ann Arbor stages I or II) can get either radiation therapy alone or radiation therapy along with chemotherapy.

Follicular Lymphoma Market

Increase in the incidence of Follicular Lymphoma as well as the expected launch of emerging therapies will boost the Follicular Lymphoma market in the forecasted period (2021–2030).

Tazverik (Tazemetostat) (Epizyme), Abexinostat (Xynomic Pharmaceuticals), ME-401 (MEI Pharma), Tisagenlecleucel (Novartis Pharmaceuticals), Parsaclisib (IBI376) (Innovent Biologics) are some of the most anticipated emerging therapies that are awaiting approval.

Know more about follicular lymphoma @ Follicular Lymphoma Market Outlook

Follicular Lymphoma Pipeline Therapies and Major Companies

• Tazverik (Tazemetostat): Epizyme

• Abexinostat: Xynomic Pharmaceuticals

• ME-401: MEI Pharma

• Tisagenlecleucel: Novartis Pharmaceuticals

• Parsaclisib (IBI376): Innovent Biologics

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

CAR T Cell Therapy for Non Hodgkin’s Lymphoma Market

Get comprehensive historical and forecast analysis of CAR T Cell Therapy for Non Hodgkin’s Lymphoma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Gilead Sciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/